This section is designed specifically for medical practitioners interested in Monovisc.
Monovisc is a single shot viscosupplements injection, designed for use in the treatment of OA of the knee. It is both the highest concentration and highest dose single shot viscosupplements currently on the market, providing patients with rapid onset, long lasting pain relief.
Monovisc is the highest concentration and dose viscosupplements on the market, delivering faster & longer lasting pain relief
as compared to other single shot injection products in their respective trials8
Monovisc treatment provided a significant number of patients with demonstrated improvement over the FDA minimum clinically important different (MCID) in WOMAC pain score between 7 and 22 weeks after injfection12
MONOVISC is a registered trademark of Anika Therapeutics, Inc., Bedford, MA 01730 U.S.A.
The information contained in this brochure applies exclusively to territories outside of USA.
1. Monovisc 0702 Pivotal Clinical Trial. FDA Monovisc Summary of Safety and Effectiveness Data 2014
2. Clinical Efficacy and Safety of MONOVISC™: A lightly cross-linked highly concentrated hyaluronan specially
formulated for single injection in osteoarthritis. White Paper Study conducted by Michael J. Daley, PhD. 2013
3. Post-Approval Study of MONOVISC™, A Symptomatic Treatment of Osteoarthritis, White Paper, 2012.